US 11,987,613 B2
Isolated T cell receptors and methods of use therefor
Angela L. Ambakhutwala, Glen Allen, VA (US); Victor H. Engelhard, Crozet, VA (US); Kara L. Cummings, Charlottesville, VA (US); and Rebecca C. Obeng, Charlottesville, VA (US)
Assigned to University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed by University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed on May 18, 2020, as Appl. No. 16/876,419.
Application 16/876,419 is a division of application No. 15/303,677, granted, now 10,654,908, previously published as PCT/US2015/025942, filed on Apr. 15, 2015.
Claims priority of provisional application 61/979,854, filed on Apr. 15, 2014.
Prior Publication US 2021/0101955 A1, Apr. 8, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/64 (2017.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); G01N 33/50 (2006.01); G01N 33/566 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 38/19 (2013.01); A61K 39/0011 (2013.01); A61K 39/001106 (2018.08); A61K 39/00111 (2018.08); A61K 39/001132 (2018.08); A61K 39/001151 (2018.08); A61K 39/001156 (2018.08); A61K 39/001157 (2018.08); A61K 39/001162 (2018.08); A61K 39/001164 (2018.08); A61K 39/001166 (2018.08); A61K 39/001181 (2018.08); A61K 39/001182 (2018.08); A61K 39/001184 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001189 (2018.08); A61K 39/001191 (2018.08); A61K 39/001192 (2018.08); A61K 39/001193 (2018.08); A61K 39/001194 (2018.08); A61K 39/001195 (2018.08); A61K 39/001197 (2018.08); A61K 45/06 (2013.01); A61K 47/6425 (2017.08); C07K 16/2809 (2013.01); G01N 33/505 (2013.01); G01N 33/566 (2013.01); G01N 33/56977 (2013.01); G01N 33/574 (2013.01); G01N 33/57484 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55533 (2013.01); C07K 2317/76 (2013.01)] 4 Claims
 
1. A method for adoptive T cell therapy in a subject with a tumor and/or a cancer that expresses a pCDC25b38-46 phosphopeptide, the method comprising administering to a subject in need thereof isolated T cell comprising an isolated nucleic acid encoding an isolated T cell receptor (TCR) or a portion thereof that specifically binds to a phosphopeptide-HLA-A2 complex, wherein the phosphopeptide has the amino acid sequence set forth in SEQ ID NO: 12, and the isolated TCR or portion thereof comprises:
an alpha chain variable domain comprising a CDR1 region sequence comprising amino acids 48-53 of SEQ ID NO: 14, a CDR2 region sequence comprising amino acids 71-77 of SEQ ID NO: 14, and a CDR3 region sequence comprising amino acids 112-121 of SEQ ID NO: 14; and
a beta chain variable domain comprising a CDR1 region sequence comprising amino acids 56-60 of SEQ ID NO: 16, a CDR2 region sequence comprising amino acids 78-83 of SEQ ID NO: 16, and a CDR3 region sequence comprising amino acids 121-129 of SEQ ID NO: 16.